Maze Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	51.94	52.23	-100.42	-114.94
Depreciation & Amortization	3.03	3.3	4.09	3.82
Loss (Gain) From Sale of Investments	-	-	-	2.4
Loss (Gain) on Equity Investments	-	-	-	3.54
Stock-Based Compensation	10.56	9.65	8.75	6.74
Other Operating Activities	7.54	12.3	7.07	2.48
Change in Accounts Payable	0.62	-0.2	0.4	-3.78
Change in Other Net Operating Assets	-3.82	-1.32	-6.72	0.54
Operating Cash Flow	69.88	75.95	-86.83	-99.2
Capital Expenditures	-1.17	-1.15	-0.44	-1.97
Investment in Securities	-	-	-	-1.2
Investing Cash Flow	-1.17	-1.15	-0.44	-3.17
Long-Term Debt Issued	-	24.48	16.18	-
Net Debt Issued (Repaid)	0.26	24.48	16.18	-
Issuance of Common Stock	128.25	0.73	0.21	0.15
Other Financing Activities	-3.65	-3.15	-	-
Financing Cash Flow	195.64	92.85	16.39	1.73
Net Cash Flow	264.35	167.65	-70.88	-100.65
Free Cash Flow	68.71	74.81	-87.27	-101.17
Free Cash Flow Margin	41.02%	44.66%	-	-
Free Cash Flow Per Share	7.38	27.40	-38.14	-50.33
Cash Income Tax Paid	1.23	1.23	-	-
Levered Free Cash Flow	-	52.09	-52.55	-
Unlevered Free Cash Flow	-	52.09	-52.55	-
Change in Net Working Capital	-	-4.31	3.35	-

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q